Remote Associate Director, Translational Biomarkers

Enliven Therapeutics, Inc.; United States; Remote; USD 205,000 - 230,000; Full time

Benefits offered by this job

Remote work flexibility

Job summary

Enliven Therapeutics, Inc. is seeking an Associate Director of Translational Medicine – Clinical Biomarkers to lead biomarker strategy and testing as part of CML programs.

You will identify and implement biomarker testing solutions, assess CRO capabilities, and build partnerships to enable high-quality biomarker assays in clinical studies. The role requires expertise in molecular biomarker assays for hematologic malignancies, including BCR::ABL1 mutation testing and transcript quantification.

Qualifications

• MD, PhD or PharmD in molecular biology, cancer biology, genetics, pathology, laboratory medicine, pharmacology, or related field.

Responsibilities

• Lead development and execution of clinical biomarker strategies for CML and oncology programs.
• Evaluate biomarker testing solutions from CROs and labs, including FDA/EMA-recognized assays.
• Establish and manage external lab partnerships with scope, timelines, budgets, and risk management.
• Review clinical protocols, lab manuals, and biomarker analysis plans with cross-functional teams.
• Collaborate with Regulatory Affairs on biomarker strategies for submissions and interactions with health authorities.
• Provide expertise on regulatory expectations for exploratory biomarkers and diagnostics.
• Support vendor audits and corrective actions with QA.

Skills

Biomarker strategy

Cross-functional collaboration

Vendor management

Regulatory awareness

Strategic thinking

Education

MD/PhD/PharmD in relevant field

MS/BS with relevant experience

Tools

NGS

Sanger sequencing

qRT-PCR

digital PCR

Job description

Enliven Therapeutics, Inc. is seeking an Associate Director of Translational Medicine – Clinical Biomarkers to lead biomarker strategy and testing as part of CML programs.

You will identify and implement biomarker testing solutions, assess CRO capabilities, and build partnerships to enable high-quality biomarker assays in clinical studies. The role requires expertise in molecular biomarker assays for hematologic malignancies, including BCR::ABL1 mutation testing and transcript quantification.